Abstract
The development of new or direct oral anticoagulants was triggered by the disadvantages of classic oral anticoagulation, which was isolated in Link’s laboratory in 1940. Some of these limitations are the individual variation in response to these drugs, drug interaction and the need for regular laboratory monitoring. With increasing comorbidity and life expectancy in populations these limitations led to interruption of treatment or even underuse of treatment in light of potential side effects. With the introduction of novel oral anticoagulants some of these drawbacks are targeted whereas even these drugs also have some limitations and should be given with cautions and not to all patients having an indication for anticoagulation.
Keywords: Coumadin, novel oral anticoagulation, thrombembolism, warfarin.
Cardiovascular & Hematological Disorders-Drug Targets
Title:Rationale for Development of New Oral Anticoagulants
Volume: 15 Issue: 2
Author(s): Muharrem Akin, Julian Widder, Ibrahim Akin, Michael Brehm and Andreas Schäfer
Affiliation:
Keywords: Coumadin, novel oral anticoagulation, thrombembolism, warfarin.
Abstract: The development of new or direct oral anticoagulants was triggered by the disadvantages of classic oral anticoagulation, which was isolated in Link’s laboratory in 1940. Some of these limitations are the individual variation in response to these drugs, drug interaction and the need for regular laboratory monitoring. With increasing comorbidity and life expectancy in populations these limitations led to interruption of treatment or even underuse of treatment in light of potential side effects. With the introduction of novel oral anticoagulants some of these drawbacks are targeted whereas even these drugs also have some limitations and should be given with cautions and not to all patients having an indication for anticoagulation.
Export Options
About this article
Cite this article as:
Akin Muharrem, Widder Julian, Akin Ibrahim, Brehm Michael and Schäfer Andreas, Rationale for Development of New Oral Anticoagulants, Cardiovascular & Hematological Disorders-Drug Targets 2015; 15 (2) . https://dx.doi.org/10.2174/1871529X1502151209110044
DOI https://dx.doi.org/10.2174/1871529X1502151209110044 |
Print ISSN 1871-529X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-4063 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Cardiovascular Risk Calculators and their Applicability to South Asians
Current Diabetes Reviews Recent Progress in Development of Non-ATP Competitive Small-Molecule Inhibitors of Protein Kinases
Mini-Reviews in Medicinal Chemistry Assessment of Cardiac Performance with Magnetic Resonance Imaging
Current Cardiology Reviews Novel Therapeutic Targets for Prevention and Therapy of Sepsis Associated Acute Kidney Injury
Current Drug Targets Modifiable Risk Factors for Premature Atherosclerosis in Systemic Lupus Erythematosus
Vascular Disease Prevention (Discontinued) Blockade of Renin Angiotensin System in Heart Failure Post-Myocardial Infarction: What is the Best Therapy?
Recent Patents on Cardiovascular Drug Discovery Vascular Sex Hormone Receptors and their Specific Modulators in the Management of Postmenopausal Cardiovascular Disease
Current Hypertension Reviews Pulmonary Drug Delivery System: A Novel Approach for Drug Delivery
Current Drug Therapy Acknowledgements to Reviewers
Current Hypertension Reviews Inhibition of the Calcineurin-NFAT Signalling Cascade in the Treatment of Heart Failure
Recent Patents on Cardiovascular Drug Discovery Organ- and Cell-Type Specific Delivery of Kinase Inhibitors: A Novel Approach in the Development of Targeted Drugs
Current Molecular Pharmacology Advances in the Treatment of Neurodegenerative Disorders Employing Nanoparticles
Recent Patents on Drug Delivery & Formulation Hypertension in Chronic Kidney Disease: Novel Insights
Current Hypertension Reviews Statins Exert Multiple Beneficial Effects on Patients Undergoing Percutaneous Revascularization Procedures
Current Drug Targets Outcomes of Treatment and Predictors of Response to Sofosbuvir Plus Simeprevir in Hepatitis C Virus with Genotype-4 Infection
Infectious Disorders - Drug Targets Outcomes of Anticoagulant Therapy with Low-Molecular-Weight Heparin (LMWH) and Warfarin for Thromboangiitis Obliterans (TAO)
Current Vascular Pharmacology Cholesterol Lowering Therapy: Treat to Target or Reduce the Global Risk? The Unresolved Problem of Residual Risk
Current Pharmaceutical Design Molecular Mechanisms of Impaired Endothelial Function Associated with Insulin Resistance
Current Drug Targets - Cardiovascular & Hematological Disorders Nitric Oxide and Disorders of the Erythrocyte: Emerging Roles and Therapeutic Targets
Cardiovascular & Hematological Disorders-Drug Targets Alcoholic Hepatitis: Pathogenesis, Diagnosis and Treatment
Reviews on Recent Clinical Trials